gastro-congress-2018-posters-abstracts

12 / 21

Page 85
Notes:
conferenceseries.com
Volume 8 Journal of Gastrointestinal & Digestive System
ISSN: 2161-069X Gastro Congress 2018
August 20-21, 2018
August 20-21, 2018 | Rome, Italy
13th Euro-Global
Gastroenterology Conference
Metanalysis: Rebamipide a potential drug for GI protection against ASA gastroenteropathy
Bienvenido P Tiu Jr
World Citi Medical Center, Philippines
Background: Aspirin has been used to lower the incidence of cardiovascular events but chronic used my lead to gastric
mucosal damage that may lead to bleeding. Rebamipide is a gastro protective agent that may reduce the risk of GI bleeding
on its pleiotropic effect by increasing gastric mucosal prostaglandin and gastric mucus production, scavenging of hydroxyl
radicals, inhibition of neutrophil activation, suppression of gastric mucosal inflammation, regulation of apoptosis related genes
and inhibition of tyrosine nitration.
Objective: To investigate whether a mucosal-protective agent, Rebamipide, could prevent gastric mucosal injuries induced by
low dose Aspirin.
Methods: Bibliographical searches were performed using PubMed and Cochrane Library. Search terms included Rebamipide
and Aspirin. A meta-analysis of all journals that were included in the inclusion criteria were reviewed comparing Rebamipide
supplementation with non-Rebamipide containing therapy was performed.
Results: Three RCTs including 579 individuals were eligible. In general, Rebamipide acted better than placebo against Aspirin-
induced gastroduodenal injury. Rebamipide showed a beneficial effect against the mucosal GIT damage. Heterogeneity of
population were computed using chi2 which shows 2.31 (df of 2, P=0.31, I2=13%). Journals included in the study were Kazuhiro
et al., with weight of 2.4%, OR of 0.13(0.02, 0.90); Takatsugu et al., with weight of 90.1%, OR of 0.32 (0.25, 0.41) and Toshio
et al., with weight of 7.5%, OR of 0.16 (0.06, 0.47). Combining the three studies yields a total (95% CI) with OR of 0.31 (0.24,
0.39).
Conclusion: Current evidences show Rebamipide is effective and safe for defending against NSAID-induced gastroduodenal
and lower-gastrointestinal injuries. However, more well-designed trials should be conducted to fully confirm the practical
value of Rebamipide.
Biography
Bienvenido P Tiu Jr. is from Philippines. He graduated from University of Santo Tomas as Bachelor of Science in Biology. He continued his medical education at Far
Eastern University - Nicanor Reyes Medical Foundation. He is currently a second year Internal Medicine resident in World Citi Medical Center.
Bienvenido P Tiu Jr, J Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C5-077